Aptus Pharma (BOM:544529) ROCE %: 36.17% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:544529 Aptus Pharma Ltd BOM:544529
18 GF Score
Price ₹269.50
! 6 Warning Signs
View Full Analysis

What is Aptus Pharma ROCE %?

Aptus Pharma BOM:544529 +3.63% 18 ROCE % is 36.17% as of Mar. 2026. GuruFocus rates BOM:544529 with a GF Score™ of 18/100. The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Aptus Pharma's annualized ROCE % for the quarter that ended in Mar. 2026 was 36.17%.

Aptus Pharma  (BOM:544529) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Aptus Pharma ROCE % Related Terms

Aptus Pharma ROCE % Historical Data

* Premium members only.

The historical data trend for Aptus Pharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aptus Pharma ROCE % Chart

Aptus Pharma Annual Data
Trend Mar23 Mar24 Mar25 Mar26
ROCE %
12.77 28.48 59.28 42.11

Aptus Pharma Semi-Annual Data
Mar23 Mar24 Sep24 Mar25 Sep25 Mar26
ROCE % Get a 7-Day Free Trial 0.00 63.28 56.88 33.07 36.17
BOM:544529
18GF Score
Aptus Pharma Ltd BOM:544529
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aptus Pharma ROCE % Calculation

Aptus Pharma's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=71.728/( ( (219.199 - 120.836) + (435.348 - 193.058) )/ 2 )
=71.728/( (98.363+242.29)/ 2 )
=71.728/170.3265
=42.11 %

Aptus Pharma's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Sep. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Sep. 2025 )(Q: Mar. 2026 )
=87.372/( ( (395.873 - 155.021) + (435.348 - 193.058) )/ 2 )
=87.372/( ( 240.852 + 242.29 )/ 2 )
=87.372/241.571
=36.17 %

(1) Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 36.17% mean?
Aptus Pharma (BOM:544529) has a ROCE % of 36.17% as of Mar. 2026.
Is Aptus Pharma's ROCE % too high?
Aptus Pharma's current ROCE % is 36.17%. The Medical Distribution industry median ROCE % is 8.92. Aptus Pharma's value of 36.17% is 305.5% above this industry median. Overall, Aptus Pharma has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Aptus Pharma's ROCE % compare to MCK and COR?
Aptus Pharma's ROCE % of 36.17% can be compared against companies in the Medical Distribution industry. The industry median ROCE % is 8.92. Aptus Pharma's value of 36.17% is 305.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Distribution company?
The median ROCE % among Medical Distribution companies is 8.92, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aptus Pharma's current ROCE % of 36.17% is 305.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Distribution industry, the median ROCE % is 8.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aptus Pharma's current ROCE % is 36.17%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aptus Pharma stock overvalued right now?
Aptus Pharma (BOM:544529) has a current ROCE % of 36.17%. The current ROCE % is 36.17% and 305.5% above the Medical Distribution industry median of 8.92. Aptus Pharma's overall GF Score™ is 18/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Aptus Pharma (BOM:544529), the current ROCE % is 36.17% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aptus Pharma Business Description

Address Narayan Nagar, Kalawad Road, SHREE Building, 1st Floor, Opp Satyasai Heart Hospital, Sau Uni Area, Rajkot, GJ, IND, 360005
Aptus Pharma Ltd is engaged in the business of marketing and distribution of finished pharmaceutical formulations. It operates through a contract manufacturing model. The group provides a diverse range of pharmaceutical products catering to various therapeutic categories, including anti-infectives, gastrointestinal, antacids, anti-allergic and respiratory, nutritional supplements, pain management, neuro-psychiatric, cardiovascular, anti-diabetic, lipid-lowering, and general wellness products. These are offered across a variety of dosage forms, such as tablets, capsules, softgels, syrups, suspensions, injections, ointments, creams, balms, drops, lotions, vials, powders, gels, and sachets.
18GF Score

Get the complete analysis for BOM:544529

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹269.50
Price